There are 2773 resources available
980P - Phase Ib study of a liposomal formulation of eribulin (E7389-LF) + nivolumab (Nivo) in patients (pts) with advanced solid tumors
Presenter: Noboru Yamamoto
Session: ePoster Display
981P - Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors
Presenter: Sarwan Bishnoi
Session: ePoster Display
923P - Nivolumab in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN) progressing on/or after a platinum-based therapy: Interim analysis of a prospective French real-world study (ProNiHN)
Presenter: Christophe Le Tourneau
Session: ePoster Display
1146P - Closing the target gap: A computational approach to optimizing therapeutic selection for cancer patients
Presenter: Mikhail Grushko
Session: ePoster Display
1147P - AI-based detection of molecular biomarkers directly from H&E scanned slide
Presenter: Nir Peled
Session: ePoster Display
1148P - Identification and validation of RET fusions in lung adenocarcinoma through DNA and RNA sequencing
Presenter: Yuchen Han
Session: ePoster Display
1085P - Ph I/II study of PI3K-β inhibitor GSK2636771 (G771) in combination with pembrolizumab (P) in patients (pts) with PTEN loss and melanoma or other advanced solid tumors
Presenter: Elizabeth Burton
Session: ePoster Display
926TiP - Phase II trial of enoblituzumab plus retifanlimab or tebotelimab in first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M SCCHN)
Presenter: Grzegorz Obara
Session: ePoster Display
1087P - The importance of anti-PD-1 dosing in the treatment of patients with inoperable or metastatic melanoma
Presenter: Bozena Cybulska-Stopa
Session: ePoster Display
1153P - Classification of multifocal lung adenocarcinomas subtypes using next-generation sequencing in pN0M0 lung adenocarcinomas
Presenter: Xin Zhang
Session: ePoster Display